Daniel Weintraub
Psychiatry · Philadelphia, PANPI 1306865779
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $628,818 of the $646,888 with a category attached, or 97.2%. Eisai Inc. accounts for 70.4% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $143,625, 2.5 times the $57,072 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $4976.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$456K
- Acadia Pharmaceuticals Inc$95K
- Novo Nordisk AS$20K
- Janssen Research & Development, LLC$15K
- AbbVie$12K
- Sunovion Pharmaceuticals Inc.$11K
- plus $38K from 13 others
Across 1 payment — averaging $600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$600
What the payments were for
- Consulting fees$628,81897%
- Travel & lodging$16,0222%
- Food & beverage$2,0480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 54 | $455,579 |
| Acadia Pharmaceuticals Inc | 27 | $94,717 |
| Novo Nordisk AS | 6 | $20,493 |
| Janssen Research & Development, LLC | 1 | $14,740 |
| AbbVie | 11 | $12,052 |
| Sunovion Pharmaceuticals Inc. | 3 | $10,999 |
| Eli Lilly | 5 | $8,912 |
| Sage Therapeutics, LLC | 5 | $7,504 |
| Boehringer Ingelheim International GmbH | 2 | $4,940 |
| Biogen | 2 | $3,566 |
| Janssen Global Services, LLC | 6 | $3,407 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,000 |
| Merck | 1 | $2,790 |
| F. Hoffmann-la Roche AG | 1 | $1,645 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,620 |
| Ferring International Pharmascience Center US | 1 | $750 |
| Idorsia Pharmaceuticals US Inc | 1 | $129 |
| Abbott | 1 | $24 |
| Johnson & Johnson | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$646,888 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 11 | $2,297 |
| Paroxetine Hcl | 23 | $511 |
| Escitalopram Oxalate | 38 | $486 |
| Lorazepam | 47 | $295 |
| Clonazepam | 77 | $238 |
| Mirtazapine | 29 | $209 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $81 |
| Trazodone Hcl | 14 | $65 |
| Alprazolam | 15 | $61 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Bianca PrevidiPhiladelphia$28K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.